“Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s279. doi:10.25251/skin.7.supp.279.